Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates ...
Patient Dosing and Enrollment Continue to Progress in Beacon Phase 1/2 Study of BEAM-101 in Severe Sickle Cell Disease; First Clinical Data Anticipated in Second Half of 2024
Source: eagletribune.com
